Approved in strengths of 1 mg, 2 mg and 4 mg, Zypitamag is an HMG-CoA reductase
inhibitor indicated for patients with primary hyperlipidemia or mixed dyslipidemia as an adjunctive therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides, and to increase high-density lipoprotein cholesterol (HDL-C).
ZYPITAMAG, which is approved in strengths of 1 mg, 2 mg and 4 mg, is an HMG-CoA reductase
inhibitor indicated for Patients with primary hyperlipidemia or mixed dyslipidemia as an adjunctive therapy to diet to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG) as well as to increase high-density lipoprotein cholesterol (HDL-C), according to the company.
Researchers from Sriwijaya University in Indonesia tested the effects of various peptides filtered out of bekasam, a fermented fish paste used in Indonesian cooking, on the enzyme HMG-CoA reductase
Statins, also known as HMG-CoA reductase
inhibitors are competitive inhibitor of the rate-limiting enzyme, 3-hydroxy 3-methylglutaryl coenzyme-A (HMG-CoA) reductase in cholesterol synthesis.
The liver was analyzed for HMG-CoA reductase
concentration and hepatic lipase activity whiles cholesterol, LDL and HDL concentrations were measured in the blood serum.
Like statin drugs, monacolins inhibit cholesterol synthesis by inhibiting HMG-CoA reductase
and also decrease C-reactive protein levels.
Statins are drugs that block a cholesterol-producing enzyme in the liver called HMG-CoA reductase
Statins might help prevent CRC through HMG-CoA reductase
inhibition and other mechanisms, according to the researchers.
The inhibition of the enzyme HMG-CoA reductase
, an essential key in the biosynthesis of cholesterol (Medina 2010; Musso et al.
Therefore, statin is referred to HMG-CoA reductase
catalyzes the reduction of HMG-CoA to mevalonate, which is the rate-limiting step in cholesterol synthesis in the liver.
Activity of plasma lipoprotein lipase (LPL), HMG-CoA reductase
and lecithin cholesterol acyltransferase (LCAT) were assayed by the method of Korn 1955, Philipp and Shapiro (1970) and Hitz et al.